Molecular Imaging For Whole Body Visualisation Of Diseases

PRISAR project (H2020-MSCA-RISE-2015) will end in January 2019. Last October, we had a final meeting with all beneficiaries representatives in Heraklion, Crete.


Percuros B.V. will take part as beneficiary into two other H2020 projects:

pHioniC - H2020-MSCA-ITN-2018 – “pH and Ion Transport in Pancreatic Cancer”
This project brings together highly synergistic expertise, research and training facilities to investigate pancreatic ductal adenocarcinoma (PDAC), a frequent and aggressive cancer that is still incurable. The programme’s central hypothesis has a strong grounding in the physiology of the exocrine pancreas. Secretion of the alkaline pancreatic juice, normally associated with digestion, leads to acidifications of the pancreas stroma resulting in an acid adaptation of pancreatic cells. We are first to propose that this adaptation facilitates PDAC initiation and progression by selecting for more aggressive phenotypes in interplay with PDAC driver mutations.
Percuros B.V. leads WP1 and is involved co-mentoring all other ESRs during progress meetings due to its expertise in molecular imaging and assay development but also in innovating and implementing advanced in vivo methods for studying and manipulating tumour growth and development.

ACORN - H2020-WIDESPREAD-05-2017 – Twinning: “A Nanoparticle-Based Therapeutic Applications and Detection of Carbon Monoxide Releasing Molecules”
The overall strategic objective of this project is to place the INSTITUTO DE MEDICINA MOLECULAR (IMM), in Lisbon, within the core of a European network of laboratories that seeks to produce cutting-edge research in the field of gaseous signalling molecules (gasotransmitters). IMM focuses, in particular, on one particular molecule in this class, which is carbon monoxide (CO).
PERC has state-of-art expertise in their use of MRI and optical imaging to monitor efficacy of therapeutic activity in small animal disease models. One technique is the use of fluorescence lifetime imaging, for which Dr Chan was a consultant for one of the leading companies in their field, ART Technologies, which is very suited to measuring gasotransmitters and hypoxia.
A key component of the project is to ensure that IMM can optimise a method for the NIRF imaging of endogenous CO in mice. This will complement the program where IMM can track and monitor the functional activity of CO being targeted to diseased areas. “
https://twitter.com/ACORN_iMM

Percuros is currently co-ordinating a European Union Marie Curie IAPP project, BRAINPATH, to build upon current developments in molecular imaging. The consortium will create an academic-industrial training and mobility network for the next revolution of imaging technology for the brain. The other partners in the consortium are Max Planck Institute for Neurological Research, Leiden University Medical Center, icoMetrix N.V., University of Antwerp, Technical University of Munich, FOM-AMOLF (Institute for Atomic and Molecular Physics and Medres GmbH.

Percuros has been awarded three more grants and will launch three projects:

  • PREPARED – A EUROSTARS funded project together with two organisations from Denmark, Atonomics and The Parker Institute (Copenhagen University Hospital), both based in Copenhagen. The program will allow the development of new point-of-care assays for therapeutic monitoring of rheumatoid arthritis.
  • CANCER – A European H2020 MSCA RISE grant to study how the new cancer immunotherapy checkpoint blockers affect patients in terms of their quality of life and the impact of such treatment on their long term immune status.
  • ARCATOR - A three-year project funded by EUROSTARS together with SIMFO GmbH, based in Bayreuth (Germany) to work on mid-throughput assays for measuring circulating tumour cells in liquid biopsies.

Percuros was recently awarded, as co-ordinator, a European Commission MSCA-ITN-2015-ETN Action grant to investigate the use of nanoparticles for combination immunotherapy. This work will be performed in conjunction with a number of European partners both for academia and industry. Nineteen early stage researchers have been recruited across the partner sites where the project will start at the end of this year. For more infomation: www.ispic.eu
MSCA-ITN-2015-ETN Action

  • On January 18 and 19 2018, TargetCaRe ESRs, PIs and partners organizations representatives met in Haifa for the sixth consortium meeting. The meeting was hosted by Technion and organized with the support of Technion and Procore. ESRs presented their progresses. Scientific discussions and mentoring sessions took place as well. The project entered in its last year, it will be a very challenging time! In addition, the fascinating location of Haifa, in Israel, gave to the consortium members the opportunity to know more about local history and culture.
    www.targetcare.eu/targetcare-consortium- meeting-in- haifa/
  • The Province of South Holland has awarded a subsidy of €200,000 to a joint project between SeraNovo and Percuros, with consultancy from Good Biomarker Sciences. The project allows SeraNovo to further develop their technology platform, while testing it on the advanced test Percuros will develop. SeraNovo’s technology allows new medicines to be absorbed in the human body that previously could not.
    https://leidenbiosciencepark.nl
  • CANCER project started in March in Nemi within the H2020 RISE programme 2017. The consortium of universities, SMEs and associations gathered for the kick-off meeting last 9 th and 10 th April in the wonderful location of Ruspoli Castel in Nemi to discuss about their future plans of action. Our aim is to study new immunotherapy approaches to improving cancer outcome and quality of life (QOL). Follow all our progresses on the project website or on our Facebook page.
    www.cancer- nemi.eu/